• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Outcomes and prognostic features of patients with influenza requiring hospitalization and receiving early antiviral therapy: A Prospective Multicenter

tetano

Editor, Senior Moderator
Chest. 2015 Jul 23. doi: 10.1378/chest.14-2768. [Epub ahead of print]
[h=1]Outcomes and prognostic features of patients with influenza requiring hospitalization and receiving early antiviral therapy: A Prospective Multicenter-Cohort Study.[/h] Maruyama T, Fujisawa T, Suga S, Nakamura H, Nagao M, Taniguchi K, Tsutsui K, Ihara T, Niederman MS.
[h=3]Abstract[/h] [h=4]Background:[/h] In Japan, routine use of early antiviral therapy for patients with influenza is standard.
[h=4]Methods:[/h] Multicenter prospective cohort evaluation of hospitalized patients with laboratory-confirmed influenza to identify prognostic factors among patients receiving antiviral therapy.
[h=4]Results:[/h] The population included 1345 influenza patients ( 766 pediatric and 579 adult), and excluding those < age 1(not approved for anti-viral therapy) , 97.7% (1224/1253) received antiviral therapy. Among 579 adult patients, 24 (4.1%) died within 30 days , while none of the 766 pediatric patients died. 528 of the adult patients (91.2%) had influenza A, 509 (87.9%) had a chronic underlying illness, 211 (36.4%) had radiographically confirmed pneumonia . 20 of the 24 patients who died, had pneumonia , and the etiologies were: Streptococcus pneumoniae (12.3%), Staphylococcus aureus (10.9%), including methicillin-resistant S. aureus (MRSA) (3.3%), Enterobacteriaceae (8.1%), and Pseudomonas aeruginosa (3.3%). Of these, 151 were classified as community-acquired pneumonia (CAP), and 60 as healthcare-associated pneumonia (HCAP). Inappropriate therapy was more common in HCAP than CAP ( 15.2% vs. 2%, p=0.001). Potential multidrug-resistant (MDR) pathogens were more common ( 21.7%vs 2.6%, p<0.001) in HCAP patients, particularly MRSA (10% vs 0.7%, p=0.002) and Pseudomonas aeruginosa (8.3% vs 1.3%, p=0.021). Using Cox proportional hazards modeling with prescribed independent variables, male gender, severity score, serum albumin (malnutrition), and pneumonia were associated with survival 30 -days from the onset of influenza.
[h=4]Conclusions:[/h] Among the prognostic factors, malnutrition and pneumonia are amenable to medical intervention. There is an opportunity to improve empiric therapy for patients with HCAP and influenza.
[h=4]Trial registration:[/h] Japan Medical Association Center for Clinical Trials JMA-IIA00123.


PMID: 26203671 [PubMed - as supplied by publisher]
 
Back
Top Bottom